A Randomized Phase III Study Of Thalidomide And Prednisone As Maintenance Therapy Following Autologous Stem Cell Transplant in Patients With Multiple Myeloma.

Trial Profile

A Randomized Phase III Study Of Thalidomide And Prednisone As Maintenance Therapy Following Autologous Stem Cell Transplant in Patients With Multiple Myeloma.

Completed
Phase of Trial: Phase III

Latest Information Update: 28 Mar 2016

At a glance

  • Drugs Thalidomide (Primary) ; Prednisone
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Feb 2011 Planned end date changed from 1 Jul 2009 to 1 Jun 2013 as reported by ClinicalTrials.gov.
    • 11 May 2010 Planned number of patients changed from 324 to 332 as reported by ClinicalTrials.gov.
    • 11 May 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top